• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Fast-Track Approval Updates in October & November 2020

Fast-Track Approval Updates in October & November 2020

Tuesday, 24 November 2020 / Published in Medical Device, News, NMPA Registration in China

Fast-Track Approval Updates in October & November 2020

During the past month, the NMPA (National Medical Device Evaluation) and CMDE (Center for Medical Device Evaluation) were actively involved in facilitating the fast-track approvals for medical devices in the Chinese market.

Procedure for Prioritized Review and Approval of Medical Devices

On October 29, the CMDE announced (No.22 – 2020) an additional set of specifications for medical devices applying for fast-track approval via the Procedure for Prioritized Review and Approval of Medical Devices.

The specifications are listed in the following:

  • The product is urgently needed for clinical use and there are no similar devices existing in the market yet.
  • The product is expected to diagnose and treat serious life-threatening diseases
  • There is currently no effective way to diagnose or treat the disease in China
  • The principle of operating the device is clear and finalized with a basic theoretical and experimental approach
  • There is sufficient clinical trial data to perform a valid assessment and to prove the product’s ability or provide clinical value

The announcement also addressed some additional information required in the basic dossier submission:

  • Clinical evaluation of the product’s condition and setting while operating
  • The clinical value of the product with data information to support
  • Evidence to show that only this product in the market has the capability to diagnose or treat the disease effectively
  • Applicants should refer to the Guidelines for Conditional Approval for Marketing of Medical Devices for dossier submission

Emergency Approval Procedure for Medical Devices

On November 5, the NMPA announced that 2 COVID-19 detection reagent products have been registered in China via the Emergency Approval Procedure for Medical Devices. According to the announcement, a total of 51 products had been registered via the procedure in 2020:

  • 24 new coronavirus nucleic acid detection reagents
  • 25 antibody detection reagents
  • 2 antigen detection reagents

Special Review Procedure for Innovative Medical Devices

On November 2, the CMDE announced that 7 domestic products and 1 overseas product (Medtronic, Inc) had been approved to apply for the Special Review Procedure for Innovative Medical Devices.

On November 11, the NMPA announced that 3 domestic products had been registered via the Special Review Procedure for Innovative Medical Devices:

  • Home test kits for colon cancer (New Horizon Health Ltd.)
  • CT diagnostic software (Yukun (Beijing) Network Technology Co., Ltd.)
  • Drug Eluting Balloon PTA Catheter (Zylox Medical Device Co.)

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Emergency Approval Procedure, fast-track approval, innovative medical device, NMPA Green Channel, Prioritized Review, Special Review Procedure

What you can read next

Public Consultation on Chemical Detection and Efficacy Evaluation Methods in Cosmetics
Webinar: MedTech pathway to China: Market opportunities, regulatory hurdles and recent updates
Cross Border E-Commerce (CBEC): 24 New Zones and New List of Retail Imported Commodities

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.